Breaking Down Shattuck Labs, Inc. (STTK) Financial Health: Key Insights for Investors

Are you keeping a close watch on your investments in the biotech sector? Specifically, how is Shattuck Labs, Inc. (STTK) navigating its financial course? As of December 31, 2024, the company holds a solid $73.0 million in cash and investments, but also reported a full-year net loss of $75.4 million, or $1.49 per share. With R&D expenses at $67.2 million for 2024, down from $74.3 million in 2023, and a strategic focus on SL-325, can Shattuck maintain its operations into 2027 as projected? Let's delve into the key financial insights that can help you make informed decisions.

Shattuck Labs, Inc. (STTK) Revenue Analysis

Analyzing Shattuck Labs, Inc. (STTK)'s revenue streams involves understanding where the company's income originates, how it has changed over time, and the relative importance of each revenue source. This information is crucial for investors to assess the company's financial health and growth potential. Here's a breakdown of key aspects to consider:

As of now, Shattuck Labs, Inc. is a clinical-stage biotechnology company and does not have products approved for sale. Therefore, it currently does not generate revenue from product sales. Instead, its financial resources primarily come from:

• Collaboration Agreements: These agreements with other pharmaceutical or biotechnology companies can provide upfront payments, milestone payments, and research funding.
• Licensing Agreements: Shattuck Labs might license its technologies or drug candidates to other companies, generating revenue through upfront fees, milestone payments, and royalties on future sales.
• Government Grants and Funding: Shattuck Labs may receive grants from government agencies or non-profit organizations to support its research and development activities.
• Investment Income: Revenue generated from the company's investments.

Given the nature of Shattuck Labs, Inc.'s operations, revenue recognition is tied to specific events outlined in their agreements, such as achieving research milestones or the progression of clinical trials. Therefore, year-over-year revenue growth is highly variable and dependent on the timing and success of these events.

Since Shattuck Labs, Inc. does not have distinct business segments in the traditional sense (like different product lines), the contribution to overall revenue is determined by the specific agreements and funding sources active during a particular period. A significant change in revenue streams would typically occur if a major collaboration agreement is signed, a licensing deal is secured, or a significant grant is awarded.

For detailed information on Shattuck Labs, Inc.’s financial performance, including revenue recognition and related notes, refer to their latest Form 10-K filing with the Securities and Exchange Commission (SEC). The Form 10-K provides a comprehensive overview of the company's financial performance, including detailed information on revenue, expenses, and cash flow.

Shattuck Labs, Inc. (STTK) Profitability Metrics

Analyzing Shattuck Labs, Inc. (STTK)'s profitability involves examining its gross profit, operating profit, and net profit margins to understand its financial health and operational efficiency. Here's a detailed look:

As of the fiscal year 2024, Shattuck Labs, Inc. presents a complex financial landscape. Detailed profitability metrics require a thorough review of their financial statements. Keep in mind that as a clinical-stage company, profitability can be heavily influenced by research and development expenses.

Here’s what we can analyze in detail:

• Gross Profit: For many clinical-stage biotech companies, gross profit can be minimal or even negative. This is often because the primary focus is on research and development rather than product sales.
• Operating Profit: Operating profit is typically negative for companies like Shattuck Labs, Inc. due to substantial R&D and clinical trial costs. Monitoring the trend of these losses is crucial; decreasing losses could indicate improved efficiency or strategic cost management.
• Net Profit Margins: Net profit margins are also usually negative for similar reasons as operating profit. Investors should pay attention to how these margins evolve, particularly in relation to significant milestones such as drug approvals or partnerships.

To provide a clearer picture, consider a hypothetical, yet indicative, financial overview:

Note: These figures are purely hypothetical and for illustrative purposes to demonstrate potential trends.

When evaluating Shattuck Labs, Inc., it's essential to compare its financial ratios against industry averages. Biotech companies often have unique financial profiles compared to other sectors, with higher R&D expenditures affecting profitability metrics.

Operational efficiency is critical for managing costs and improving gross margins over time. Key factors include:

• R&D Expenses: Efficient allocation and management of research and development costs are vital.
• Clinical Trial Success: Positive clinical trial outcomes can significantly boost investor confidence and potentially lead to revenue-generating partnerships.
• Strategic Partnerships: Collaborations can provide financial support and accelerate drug development.

For more insights into who is investing in Shattuck Labs, Inc. and why, check out: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?

Shattuck Labs, Inc. (STTK) Debt vs. Equity Structure

Here's an overview of how Shattuck Labs, Inc. (STTK) finances its growth, focusing on its debt and equity structure as of fiscal year 2024.

Overview of Debt Levels

• Short-Term Debt: As of December 31, 2024, Shattuck Labs Inc. reports $0 USD in short-term debt.
• Long-Term Debt: Shattuck Labs has $0.0 total debt.

Debt-to-Equity Ratio

• As of December 2024, Shattuck Labs has a debt-to-equity ratio of 0%.

Recent Debt Activity

• As of April 2025, there are no recent debt issuances, credit ratings, or refinancing activities available.

Balancing Debt and Equity

Shattuck Labs primarily relies on equity funding. The company had cash and cash equivalents and investments of approximately $73.0 million as of December 31, 2024, compared to $130.6 million as of December 31, 2023.

Here's a brief overview in a table format:

For more detailed insights into Shattuck Labs, Inc. (STTK) financial health, you can check out this resource: Breaking Down Shattuck Labs, Inc. (STTK) Financial Health: Key Insights for Investors

Shattuck Labs, Inc. (STTK) Liquidity and Solvency

Understanding Shattuck Labs, Inc.'s (STTK) financial health requires a close examination of its liquidity and solvency. These metrics provide insights into the company's ability to meet its short-term and long-term obligations.

Liquidity Positions:

• Current Ratio: A vital measure of liquidity, the current ratio assesses a company's capability to cover its short-term liabilities with its short-term assets.
• Quick Ratio: Also known as the acid-test ratio, the quick ratio offers a more conservative view by excluding inventories from current assets, focusing on the most liquid assets.

Analyzing these ratios helps determine if Shattuck Labs, Inc. (STTK) has sufficient liquid assets to handle its immediate financial obligations.

Working Capital Trends:

Monitoring the trends in working capital—the difference between current assets and current liabilities—is crucial. A positive working capital balance indicates that a company has enough short-term assets to cover its short-term liabilities. Fluctuations in working capital can signal potential liquidity issues or improvements.

Cash Flow Statements Overview:

Cash flow statements provide a detailed look at how Shattuck Labs, Inc. (STTK) generates and uses cash. There are three key areas to consider:

• Operating Cash Flow: This reflects the cash generated from the company's core business activities.
• Investing Cash Flow: This includes cash used for investments in assets, such as property, plant, and equipment.
• Financing Cash Flow: This involves cash flow related to debt, equity, and dividends.

Examining these cash flow trends can reveal whether the company is generating enough cash to sustain its operations, invest in future growth, and meet its financial obligations. For additional insights into the company's strategic direction, consider exploring Mission Statement, Vision, & Core Values of Shattuck Labs, Inc. (STTK).

Potential Liquidity Concerns or Strengths:

Identifying potential liquidity concerns or strengths involves analyzing the data gathered from the ratios, working capital, and cash flow statements. For instance, a declining current ratio coupled with negative operating cash flow might signal liquidity issues. Conversely, a strong current ratio and positive operating cash flow suggest a solid liquidity position.

Shattuck Labs, Inc. (STTK) Valuation Analysis

Determining whether Shattuck Labs, Inc. (STTK) is overvalued or undervalued requires a multifaceted approach, incorporating several key financial metrics and market analyses. Here's a breakdown of essential valuation indicators:

Currently, Shattuck Labs, Inc. (STTK) does not have a price-to-earnings (P/E) ratio, nor a forward P/E ratio, due to the company's current lack of earnings. Similarly, with negative earnings, determining an accurate price-to-book (P/B) ratio or enterprise value-to-EBITDA (EV/EBITDA) is challenging. These metrics are typically used to compare a company’s market value to its book value or earnings before interest, taxes, depreciation, and amortization, respectively.

Analyzing stock price trends provides insight into market sentiment and historical performance. Over the past year, STTK's stock has experienced volatility. As of April 17, 2025, STTK is trading at $3.44. The stock's 52-week range is between $1.85 and $14.40, reflecting significant price fluctuations. These fluctuations could be attributed to various factors, including clinical trial outcomes, market conditions, and investor sentiment.

Given that Shattuck Labs, Inc. is a development-stage company, it does not currently offer a dividend yield or have established payout ratios. These are more common metrics for mature, profitable companies that return a portion of their earnings to shareholders.

Analyst consensus on STTK stock provides a forward-looking perspective. The consensus among analysts is that the stock is a moderate buy. The average target price is $15.00, suggesting a potential upside of 336% from the current price of $3.44. The range of analyst ratings varies, with a high target of $31.00 and a low target of $8.00. These targets reflect different analysts' perspectives on the company's future performance and prospects.

To summarize, consider the following points:

• P/E Ratio: Not applicable due to negative earnings.
• P/B Ratio: Difficult to assess accurately due to negative earnings.
• EV/EBITDA: Not applicable due to negative EBITDA.
• Stock Price Trends: Current price is $3.44, with a 52-week range of $1.85 to $14.40.
• Dividend Yield and Payout Ratios: Not applicable as STTK does not currently pay dividends.
• Analyst Consensus: Moderate Buy with an average target price of $15.00.

For further insights into investor behavior and stock performance, check out: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?

Shattuck Labs, Inc. (STTK) Risk Factors

Understanding the risks facing Shattuck Labs, Inc. (STTK) is crucial for investors assessing the company's financial health and future prospects. These risks can stem from both internal and external factors, impacting operational efficiency, financial stability, and strategic direction.

Here's an overview of key risks that Shattuck Labs, Inc. (STTK) may face:

• Industry Competition: The biotechnology industry is intensely competitive. Shattuck Labs, Inc. (STTK) faces competition from other pharmaceutical and biotechnology companies, including those with greater financial resources, established infrastructure, and larger research and development teams. This competition can affect the company's ability to successfully develop, commercialize, and market its products.
• Regulatory Changes: The development, manufacturing, and marketing of pharmaceutical products are subject to extensive regulation by government authorities, including the FDA in the United States and similar bodies in other countries. Changes in regulatory requirements or delays in obtaining regulatory approvals can significantly impact Shattuck Labs, Inc. (STTK)'s timelines and costs.
• Market Conditions: Unfavorable market conditions, such as economic downturns or changes in healthcare spending, can affect the demand for Shattuck Labs, Inc. (STTK)'s products. Additionally, changes in investor sentiment towards the biotechnology industry can impact the company's stock price and ability to raise capital.

Operational, financial, and strategic risks can be identified from recent earnings reports or filings. These may include:

• Clinical Trial Risks: Shattuck Labs, Inc. (STTK)'s product development pipeline relies on the success of clinical trials. Clinical trials are inherently risky and may not demonstrate the desired safety and efficacy results. Delays, setbacks, or failures in clinical trials can significantly impact the company's prospects.
• Manufacturing Risks: Manufacturing pharmaceutical products is complex and requires adherence to strict quality control standards. Shattuck Labs, Inc. (STTK) may face risks related to manufacturing yields, product quality, and supply chain disruptions.
• Commercialization Risks: Even if Shattuck Labs, Inc. (STTK) successfully develops and obtains regulatory approval for its products, there is no guarantee that they will be commercially successful. Market acceptance, pricing pressures, and competition from other products can affect the company's ability to generate revenue.
• Financial Risks: Shattuck Labs, Inc. (STTK) may face financial risks related to its ability to raise capital, manage its expenses, and achieve profitability. The company's financial performance can be affected by factors such as research and development costs, clinical trial expenses, and marketing expenses.

Mitigation strategies or plans, if available, may include:

• Diversifying Product Pipeline: Shattuck Labs, Inc. (STTK) may mitigate clinical trial risks by diversifying its product pipeline and pursuing multiple drug candidates.
• Strategic Partnerships: Collaborating with other companies can help Shattuck Labs, Inc. (STTK) share the risks and costs of drug development and commercialization.
• Risk Management Programs: Implementing robust risk management programs can help Shattuck Labs, Inc. (STTK) identify, assess, and mitigate potential risks.

For additional insights into Shattuck Labs, Inc. (STTK)'s financial health, you can explore: Breaking Down Shattuck Labs, Inc. (STTK) Financial Health: Key Insights for Investors

Shattuck Labs, Inc. (STTK) Growth Opportunities

Shattuck Labs, Inc. (STTK) is focusing on developing novel cancer therapeutics, particularly through its Agonist Redirected Checkpoint (ARC) platform. This platform is designed to simultaneously block checkpoint inhibitors and activate TNF superfamily receptors to enhance the immune response against tumors.

Key growth drivers for Shattuck Labs, Inc. (STTK) include:

• Product Innovations: Advancing the ARC platform and developing new therapies that can improve patient outcomes in various cancer types.
• Market Expansion: Targeting markets with high unmet needs in cancer treatment, potentially through strategic partnerships or collaborations.
• Strategic Initiatives: Focusing on clinical trials and regulatory approvals to bring their innovative therapies to market.

While specific future revenue growth projections and earnings estimates for Shattuck Labs, Inc. (STTK) are not available in the provided search results, information on financial performance can be found in their annual reports and investor presentations.

Shattuck Labs, Inc. (STTK) is actively pursuing strategic initiatives and partnerships to drive future growth. For instance, they are involved in multiple clinical trials to evaluate the efficacy and safety of their ARC therapies in different cancer indications.

Shattuck Labs, Inc. (STTK)'s competitive advantages include its innovative ARC platform, which has the potential to offer a more effective approach to cancer immunotherapy compared to traditional methods. The company's focus on dual-mechanism therapies that both activate and redirect the immune system may provide a unique edge in the competitive landscape.

More insights into Shattuck Labs, Inc. (STTK)'s financial health can be found here: Breaking Down Shattuck Labs, Inc. (STTK) Financial Health: Key Insights for Investors